Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 15/12/2019
SIETES contiene 92856 citas

 
 
 1 a 20 de 470 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S, GS-US-292-0104/0111 Study Team. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015;385:2606-15. [Ref.ID 99315]
2. Cita con resumen
Anónimo. Etravirine et HIV chez les enfants de plus de 6 ans. Prescrire 2014;34:416. [Ref.ID 97946]
3. Cita con resumen
Anónimo. Dolutégravir. Prescrire 2014;34:414-5. [Ref.ID 97945]
4. Cita con resumen
Anónimo. Raltégravir et HIV chez les enfants de plus de 2 ans. Prescrire 2014;34:413. [Ref.ID 97944]
5. Cita con resumen
Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 2014;384:258-71. [Ref.ID 97821]
6. Cita con resumen
Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbel TB, Sax PE, Gulick RM, O'Keefe L, Robertson KR, Tierney C. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med 2014;161:1-10. [Ref.ID 97795]
9. Cita con resumen
Anónimo. Dolutegravir (Tivicay) for HIV. Med Lett Drugs Ther 2013;55:77-9. [Ref.ID 96249]
10.Tiene citas relacionadas Cita con resumen
Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S, on behalf of the SRPING-2 study group. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013;381:735-43. [Ref.ID 95046]
11.Tiene citas relacionadas
Waters LJ, Barber TJ. Dolutegravir for treatment of HIV: SPRING forwards?. Lancet 2013;381:705-6. [Ref.ID 95045]
12.Tiene citas relacionadas
Török ME, Farrar JJ. When to start antiretroviral therapy in HIV-associated tuberculosis. N Engl J Med 2011;365:1538-40. [Ref.ID 91585]
13.Tiene citas relacionadas
Karim SSA, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, Gengiah T, Gengiah S, Naidoo A, Jihoo N, Nair G, El-Sadr WM, Friedland G, Karim QA. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011;365:1492-501. [Ref.ID 91584]
14.Tiene citas relacionadas
Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, Hakim J, Mohapi L, Mugyenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash A, Moko E, Sawe F, Andersen J, Sanne I, for the AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011;365:1482-91. [Ref.ID 91583]
15.Tiene citas relacionadas Cita con resumen
Blanc F-X, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, Madec Y, Marcy O, Chan S, Prak N, Kim C, Lak KK, Hak C, Dim B, Sin CI, Sun S, Guillard B, Sar B, Vong S, Fernandez M, Fox L, Delfraissy J-F, Goldfeld AE, for the CAMELIA (ANRS 1295-CIPRA KH001) Study Team. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011;365:1471-81. [Ref.ID 91582]
16. Cita con resumen
The Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med 2010;170:410-9. [Ref.ID 88063]
17. Cita con resumen
de Bruin M, Viechtbauer W, Schaalma HP, Kok G, Abraham C, Hospers HJ. Standard care impact on effects of highly active antiretroviral therapy adherence interventions. A meta-analysis of randomized controlled trials. Arch Intern Med 2010;170:240-50. [Ref.ID 87849]
18.Tiene citas relacionadas Cita con resumen
Lennox JL, DeJesus E, Lazzarín A, Pollard RB, Madruga J, Berger DS, Zhao J, Xu X, Williams-Díaz A, Rodgers AJ, Barnard RJO, Miller MD, DiNubile MJ, Nguyen B-Y, Leavitt R, Sklar P, for the STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009;374:796-806. [Ref.ID 86738]
19.Tiene citas relacionadas
Emery S, Winston A. Raltegravir: a new choice in HIV and new chances for research. Lancet 2009;374:764-6. [Ref.ID 86736]
20. Cita con resumen
Volari A, Paed MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, Jean-Philippe P, McIntyre JA, for the CHER Study Team. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008;359:2233-44. [Ref.ID 84525]
Seleccionar todas
 
 1 a 20 de 470 siguiente >>